Fatty acid synthase is a metabolic oncogene targetable in malignant peripheral nerve sheath tumors

Ami V Patel1, Gunnar Johansson1, Melissa C Colbert1

  • 1Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, Ohio, USA (A.V.P., N.R.); Division of Oncology, Cincinnati Children's Hospital, Cincinnati, Ohio, USA (B.D.); Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden (G.J.); Assistant Director for Compliance, Office of Intramural Research, National Institute of Health (M.C.C.).

Neuro-Oncology
|June 28, 2015
PubMed
Abstract

Insights

Malignant peripheral nerve sheath tumors (MPNSTs) rely on lipid metabolism for survival. Inhibiting fatty acid synthesis or oxidation significantly reduces MPNST growth, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Sarcoma Research

Background:

  • Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with limited treatment options.
  • Accumulation of lipid droplets (LDs) was observed in human MPNST cell lines and tumor samples.
  • This study investigated the role of lipid metabolism in MPNST progression and therapeutic potential.

Purpose of the Study:

  • To determine the relevance of lipid metabolism to MPNST cell survival and proliferation.
  • To explore lipid metabolism as a potential therapeutic target for MPNSTs.

Main Methods:

  • Examined cellular respiration and the role of fatty acid oxidation (FAO) in MPNSTs.
  • Investigated fatty acid synthase (FAS) activity in de novo fatty acid synthesis.
  • Utilized genetic and pharmacological approaches to inhibit lipid metabolic pathways.

Main Results:

  • Lipid droplets (LDs) were confirmed to accumulate in MPNST cells and tumors, and could be oxidized for energy.
  • Inhibition of FAO reduced oxygen consumption and MPNST cell survival.
  • Inhibition of de novo fatty acid synthesis, which is upregulated in MPNSTs, decreased cell survival and tumor growth in vivo.

Conclusions:

  • MPNSTs exhibit a significant dependence on lipid metabolic pathways.
  • Disrupting lipid metabolism presents a promising novel therapeutic strategy for MPNST treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K